KDR and non-small cell lung carcinoma: Interestingly, the glucose metabolism alterations seem to be attached mostly to alterations in the PI3K-Akt pathway; this could be explained by what Pal et al. found in a study looking for the effects of DS3 in non-small-cell Lung Cancer Cells (NSCLC) [18], by targeting EGRF/VEGFR2.